Upstream Bio, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Upstream Bio, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Growth Efficiency Ratio: Sales grew 135% in 3 years, but profit fell: $7,282 less profit per $100 of extra sales. Lower than almost all Healthcare companies in United States.
- Cash Cushion Ratio: Cash, after subtracting all debt, is 2.1 times its market value (net cash). Higher than 96% of Healthcare companies in United States.
- Self-Funding Ratio: Over the last 3 years operating cash was negative while the company kept spending on investment (capex). Lower than 92% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-280.9×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 92% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
2/3 · 1/3Sales grew in 2 of the last 3 years; profit grew in 1 of 3.
Steadier than 50% of Healthcare companies in United States.
Growth Efficiency Ratio
−$7,282Sales grew 135% in 3 years, but profit fell: $7,282 less profit per $100 of extra sales.
Lower than almost all Healthcare companies in United States.
Asset Productivity Ratio
+135% / +1815%In 3 years sales changed by +135% while total assets changed by +1815%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-185.1×Operating cash was negative last year, while some debt falls due within a year.
Lower than 92% of Healthcare companies in United States.
Cash Cushion Ratio
2.1× cashCash, after subtracting all debt, is 2.1 times its market value (net cash).
Higher than 96% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Upstream Bio, Inc. made a loss over the last year. Upstream Bio, Inc. owes $0.04 for every $1 it owns. Upstream Bio, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossUpstream Bio, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.60The share price is 0.60 times Upstream Bio, Inc.'s book value per share, lower than 88% of Healthcare companies in United States.
Market cap
$164 MThe total market value of all of Upstream Bio, Inc.'s shares at today's price (share price × number of shares), smaller than 60% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$271 MWhat Upstream Bio, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$4.95Net worth divided by the number of shares. The share price of $2.99 is 0.6 times this, which is the P/B above.
Return on equity (ROE)
-46.0%Upstream Bio, Inc. lost 46.0% of its shareholders' money over the last year, higher than 52% of Healthcare companies in United States.
Owes vs Owns
0.04×Upstream Bio, Inc. owes $0.04 for every $1 it owns (low), lower than 98% of Healthcare companies in United States.
Dividend yield
NoneUpstream Bio, Inc. does not currently pay a dividend.
Revenue growth
+20%Revenue rose 20% in the year to Dec 2025, and grew 33% a year on average over 3 years.
Profit growth
LossUpstream Bio, Inc. made a loss in each of the last two years.
Profit margin
-5026.0%Upstream Bio, Inc. lost $5026 for every $100 of revenue.
Cash vs debt
Net cashUpstream Bio, Inc. held $340 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Upstream Bio, Inc.: $164 M ÷ $271 M (30 Jun 2026) = 0.6.
What is Upstream Bio, Inc.'s return on equity?
Upstream Bio, Inc. lost 46.0% of its shareholders' money over the last year, higher than 52% of Healthcare companies in United States.
How much does Upstream Bio, Inc. owe compared with what it owns?
Upstream Bio, Inc. owes $0.04 for every $1 it owns (low), lower than 98% of Healthcare companies in United States.
Does Upstream Bio, Inc. pay a dividend?
No. Upstream Bio, Inc. does not currently pay a dividend.
Is Upstream Bio, Inc.'s revenue growing?
Revenue rose 20% in the year to Dec 2025, and grew 33% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.